glp 1 safety GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Pulmonary Aspiration Warning for GLP-1
Description
HR = 0.83
Finally, what factors do we need to consider in our healthcare system to ensure that patients have appropriate (and likely chronic) access to expensive biologic medications
GaoXZhaoSDuYYangZTianYZhaoJet al
These include pancreatitis, gallbladder problems, bowel obstruction, vision problems, kidney injury, and severe allergic reactions
Those 5 obstacles I hit at the beginning of the article are all being tackled
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes
